Application of Cultured Autologous Keratinocytes for Burn Wound Healing (KC)
Primary Purpose
Burns
Status
Completed
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Cultured autologous keratinocytes
Sponsored by
About this trial
This is an interventional treatment trial for Burns focused on measuring Burns, Cultured autologous keratinocytes, Wound healing, Wound closure, Scar quality
Eligibility Criteria
Inclusion Criteria:
- Competent and temporarily incompetent patients 18 years of age or older with acute burn wounds that require widely meshed skin grafting, which do not need immediate excision
- Minimal study wound area 100 cm2
- Maximal study wound area 300 cm2
- Maximal TBSA 30% full thickness wounds
- Informed consent
Exclusion Criteria:
- Immunocompromised patients
- Infected wounds
- Use of high doses of (.20mg/pd) corticosteroids and/or cytostatica
- Known penicillin allergy
- Conditions where the patient is non compliant as judged by a medical specialist
Sites / Locations
- Red Cross Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
1
2
Arm Description
wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
control wound site; application of mesh graft alone
Outcomes
Primary Outcome Measures
Primary end point is the percentage of wound closure.
Secondary Outcome Measures
Secondary objective is scar quality (i.e. subjective scar assessment, scar elasticity, colour and pigmentation of the scar and smoothness of the scar surface).
Full Information
NCT ID
NCT00832156
First Posted
January 28, 2009
Last Updated
February 13, 2020
Sponsor
Association of Dutch Burn Centres
1. Study Identification
Unique Protocol Identification Number
NCT00832156
Brief Title
Application of Cultured Autologous Keratinocytes for Burn Wound Healing
Acronym
KC
Official Title
Application of Cultured Autologous Keratinocytes in Combination With a Meshed Split Skin Autograft for Burn Wound Healing
Study Type
Interventional
2. Study Status
Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
June 2008 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
September 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Association of Dutch Burn Centres
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this study the treatment of full thickness burn wounds with cultured autologous keratinocytes in combination with meshed split skin autograft versus meshed split skin graft alone will be compared. It is expected that the application of cultured autologous keratinocytes in combination with a meshed split skin autograft will improve wound healing and scar formation.
Detailed Description
The standard treatment for extensive burn wounds is transplantation with meshed split skin graft. Disadvantages of this treatment are that healing of large full thickness burn wounds is still accompanied by scar formation. Even standard treatment, transplantation with a (meshed) split skin autograft, does not result in satisfactory functional and cosmetic appearance of the healed wound. Due to limited available donor sites meshes needs to be enlarged. Bigger enlargements of meshes give more scarring and mesh pattern are still visible in scars, probably because wound closure still needs several weeks. Application of cultured autologous keratinocytes may enhance wound closure and improve outcome of healing.
Primary objective: Does the application of cultured autologous keratinocytes on deep burn wounds accelerate wound closure Secondary objectives: Does the application of cultured autologous keratinocytes on deep burn wounds improve scar quality with respect to scar elasticity, colour/pigmentation and/or smoothness after 3 and 12 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Burns
Keywords
Burns, Cultured autologous keratinocytes, Wound healing, Wound closure, Scar quality
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
Arm Title
2
Arm Type
Other
Arm Description
control wound site; application of mesh graft alone
Intervention Type
Biological
Intervention Name(s)
Cultured autologous keratinocytes
Other Intervention Name(s)
Cultured keratinocytes
Intervention Description
The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
Primary Outcome Measure Information:
Title
Primary end point is the percentage of wound closure.
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Secondary objective is scar quality (i.e. subjective scar assessment, scar elasticity, colour and pigmentation of the scar and smoothness of the scar surface).
Time Frame
3 and 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Competent and temporarily incompetent patients 18 years of age or older with acute burn wounds that require widely meshed skin grafting, which do not need immediate excision
Minimal study wound area 100 cm2
Maximal study wound area 300 cm2
Maximal TBSA 30% full thickness wounds
Informed consent
Exclusion Criteria:
Immunocompromised patients
Infected wounds
Use of high doses of (.20mg/pd) corticosteroids and/or cytostatica
Known penicillin allergy
Conditions where the patient is non compliant as judged by a medical specialist
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
E Middelkoop, Prof
Organizational Affiliation
Association of Dutch Burn Centers
Official's Role
Study Director
Facility Information:
Facility Name
Red Cross Hospital
City
Beverwijk
State/Province
Noord-Holland
ZIP/Postal Code
1942 LE
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
Application of Cultured Autologous Keratinocytes for Burn Wound Healing
We'll reach out to this number within 24 hrs